Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) had its target price lowered by equities research analysts at The Goldman Sachs Group from $58.00 to $41.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. The Goldman Sachs Group‘s target price would indicate a potential upside of 42.48% from the company’s current price.
IONS has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research note on Thursday, October 15th. HC Wainwright reduced their price target on shares of Ionis Pharmaceuticals from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday. Wolfe Research lowered shares of Ionis Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a report on Thursday, July 16th. Guggenheim lowered their price objective on shares of Ionis Pharmaceuticals from $89.00 to $80.00 and set a “buy” rating for the company in a research report on Tuesday, September 15th. Finally, Royal Bank Of Canada dropped their target price on shares of Ionis Pharmaceuticals from $85.00 to $60.00 and set an “outperform” rating on the stock in a research note on Tuesday. Nineteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Ionis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $78.00.
Read Our Latest Stock Analysis on IONS
Ionis Pharmaceuticals Trading Down 7.2%
Ionis Pharmaceuticals stock traded down $2.23 during midday trading on Tuesday, reaching $28.77. The stock had a trading volume of 2,526,241 shares, compared to its average volume of 2,744,755. Ionis Pharmaceuticals has a 52-week low of $27.75 and a 52-week high of $86.74. The company has a fifty day moving average of $46.20 and a 200 day moving average of $65.63. The firm has a market cap of $4.78 billion, a price-to-earnings ratio of -8.36 and a beta of 0.43. The company has a quick ratio of 7.73, a current ratio of 7.89 and a debt-to-equity ratio of 3.07.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative return on equity of 111.08% and a negative net margin of 64.76%. The firm had revenue of $242.72 million for the quarter, compared to the consensus estimate of $178.17 million. During the same period in the prior year, the business posted ($0.80) earnings per share. The company’s revenue for the quarter was up 54.8% on a year-over-year basis. On average, analysts anticipate that Ionis Pharmaceuticals will post -3.62 earnings per share for the current fiscal year.
Insider Buying and Selling at Ionis Pharmaceuticals
In other news, EVP Shannon Devers sold 1,357 shares of the firm’s stock in a transaction on Friday, October 16th. The stock was sold at an average price of $43.54, for a total value of $59,083.78. Following the completion of the sale, the executive vice president owned 17,811 shares of the company’s stock, valued at $775,490.94. This trade represents a 7.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 1.81% of the stock is owned by insiders.
Institutional Investors Weigh In On Ionis Pharmaceuticals
Large investors have recently modified their holdings of the business. Alyeska Investment Group L.P. boosted its stake in Ionis Pharmaceuticals by 199.7% in the 2nd quarter. Alyeska Investment Group L.P. now owns 1,417,916 shares of the company’s stock worth $112,427,000 after purchasing an additional 944,766 shares in the last quarter. Pictet Asset Management Holding SA increased its stake in Ionis Pharmaceuticals by 21.7% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,944,020 shares of the company’s stock valued at $87,249,000 after purchasing an additional 347,022 shares in the last quarter. Bank of America Corp DE acquired a new position in Ionis Pharmaceuticals during the 2nd quarter valued at approximately $62,718,000. Groupama Asset Managment raised its holdings in shares of Ionis Pharmaceuticals by 7.5% in the first quarter. Groupama Asset Managment now owns 824,540 shares of the company’s stock worth $61,915,000 after buying an additional 57,651 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Ionis Pharmaceuticals in the second quarter worth $54,253,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.
Key Ionis Pharmaceuticals News
Here are the key news stories impacting Ionis Pharmaceuticals this week:
- Positive Sentiment: Ionis reported third-quarter revenue of about $243 million, up roughly 55% year over year and above expectations. Its quarterly loss was also narrower than analysts had forecast. Read More.
- Positive Sentiment: DAWNZERA sales grew 40% to $37 million, providing a positive commercial update amid weakness in TRYNGOLZA’s launch. Read More.
- Negative Sentiment: Ionis cut its 2026 TRYNGOLZA sales outlook to approximately $50 million, down from its prior $100 million–$110 million target. The company cited slower-than-expected uptake and competitive pressure, undermining expectations for the drug’s commercial potential. Read More.
- Negative Sentiment: Ionis guided to 2026 revenue of $875 million–$900 million, below the roughly $921 million consensus estimate, adding to concerns about near-term growth. Read More.
- Negative Sentiment: Law firms announced investigations into potential investor claims related to Ionis, adding a legal overhang following the sales forecast reduction. These announcements concern potential claims and do not establish wrongdoing. Read More.
- Negative Sentiment: HC Wainwright and Needham lowered their price targets to $70 and $54, respectively, although both maintained Buy ratings. Read More. · Read More.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.
Featured Articles
- Five stocks we like better than Ionis Pharmaceuticals
- Fox’s $22 Billion Roku Acquisition Reshapes Its Streaming Business
- DraftKings Just Lost 20%—And Its Biggest Gamble Is Still Ahead
- Barrick’s Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity
- Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
